ALBME Releases Guidelines for Off-Label Use of Ketamine for Outpatient Tx of TRD
In August 2025, after consideration of recent national trends in the off-label use of ketamine in outpatient settings for the treatment of treatment-resistant depression (TRD), the National Protocol Guidance concerning the use of ketamine for TRD published by the Department of Veterans Affairs, and research and consultation with subject matter experts, the Alabama Board of Medical Examiners issued this position statement and guidelines for the off-label use of ketamine for the treatment of TRD in outpatient settings.